Drugs / AD-120A
Trials 1
| Phase | Registry id | Dates | Indication | Sponsor | Status | Outcome |
|---|---|---|---|---|---|---|
| Phase 1 | NCT06916130 | Apr → Sep 2025 overdue | gastroesophageal reflux disease | Addpharma Inc. | Not yet recruiting | No outcome recorded |
Evidence & citations 2 cited values
Every value below carries the sentence it was read from. 1 source stands behind the page.
| Field | Value | Cited text |
|---|---|---|
| Known as | AD-120A | ClinicalTrials.gov intervention name — accepted as the source's own label NCT06916130 ↗ |
| Route | Oral | “Administered before the breakfast during 7 days, Oral, Tablet” NCT06916130 ↗ |